ROIV — Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: GB
- Exchange: NASDAQ
- Employees: 908
- Website: https://roivant.com
Latest SEC filings for ROIV
- SCHEDULE 13D/A — 2026-10-06
- 8-K — 2026-08-28
- 8-K — 2026-08-27
- SCHEDULE 13G/A — 2026-08-13
- 8-K — 2026-08-06
- 10-Q — 2026-08-06
- ARS — 2026-07-29
- S-8 — 2026-05-20
- 10-K — 2026-05-20
- 8-K — 2026-05-20
Latest ROIV news
- — Roivant to seek label expansion for Lisraya in uveitis after late-stage trial win (seekingalpha_market)
- — Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) (GlobeNewswire Inc.)
- — Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 (GlobeNewswire Inc.)
- — Roivant Sciences added to Citi's 90-day catalyst watch (seekingalpha_market)
- — Roivant’s Eric Venker sells 200,000 shares after option exercise (NASDAQ: ROIV) (defenseworld.net)
- — Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months (marketbeat.com)
Educational tool only — not investment advice.